Targeting PD-1 or PD-L1 with specific immune checkpoint inhibitors (ICIs) to prevent their interaction yielded dramatic results and improved outcomes in several hard-to-treat cancers, including melanoma, urothelial carcinoma, small-cell and non-small-cell lung cancer (NSCLC) [2,3,4,5,6,7,8,9,10,11,12,13]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.